Drug or treatment

Isatuximab clinical trials

• 23Clinical trials
• 1New in 30 days
• 14Countries

Newest trials

All recruiting trials (23)

• QLS4131 plus isatuximab for newly diagnosed primary plasma cell leukemia

  This trial tests whether a BCMA/GPRC5D/CD3 trispecific antibody (QLS4131) added to isatuximab can help adults with newly diagnosed primary plasma cell leukemia see better treatment responses.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07903623

• Isatuximab-VRd for transplant-ineligible newly diagnosed multiple myeloma

  This study tests Isa-VRd in real-world Chinese patients who are newly diagnosed and cannot undergo stem cell transplant to see how well it works and how safe it is.

  Recruiting at 13 sites Shanghai Zhongshan Hospital · Beijing, Beijing Municipality and 12 other locations · NCT07663253

• CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia

  A new combination therapy using CM336 with isatuximab, lenalidomide, and bortezomib is being tested in adults newly diagnosed with primary plasma cell leukemia to see if it can improve treatment responses and safety.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07652905

• Isatuximab, Iberdomide, Bortezomib, and Dexamethasone Induction in New Myeloma, Followed by Adaptive Consolidation and Maintenance for Transplant-Eligible Patients

  This study tests a combination therapy for newly diagnosed, transplant-eligible multiple myeloma patients to see if risk- and response-guided maintenance and consolidation can improve outcomes.

  Recruiting Phase 3 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07624513

• CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment

  This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07585760

• Selinexor with Carfilzomib, Isatuximab and Dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether a four-drug combination can help adults with relapsed or refractory multiple myeloma when they've had at least one prior treatment.

  Recruiting Phase 1/2 Hoosier Cancer Research Network · Madison, Wisconsin · NCT07479979

• Evaluating Isatuximab Treatments for Relapsed Multiple Myeloma with 1q21+

  This study is testing if a combination of isatuximab with other medications can help people with relapsed multiple myeloma who have a specific genetic marker called 1q21+.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06874530

• Elranatamab plus under-the-skin isatuximab for relapsed/refractory multiple myeloma

  This trial will test whether combining elranatamab with subcutaneous isatuximab helps people with relapsed or refractory multiple myeloma who have had at least two prior therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06832865

• Isatuximab plus iberdomide and dexamethasone for people with intermediate- or high-risk smouldering myeloma

  This trial will test whether combining isatuximab, iberdomide, and dexamethasone can delay or prevent progression to active multiple myeloma in adults with intermediate- or high-risk smouldering myeloma.

  Recruiting at 14 sites Phase 2 University College, London · Leeds, Leeds and 13 other locations · NCT06762769

• Treatment for CD38 Positive T-cell Acute Lymphoblastic Leukemia

  This study is testing if a new drug called Isatuximab can help adults with a tough type of leukemia called CD38 positive T-cell acute lymphoblastic leukemia that has come back or didn’t respond to other treatments.

  Recruiting at 15 sites Phase 2 Goethe University · Augsburg and 14 other locations · NCT06648889

• Go-slow isatuximab and dexamethasone with later lenalidomide for ultra-frail multiple myeloma patients

  This trial will try a gentle, phased start of isatuximab and dexamethasone, adding lenalidomide later, for newly diagnosed, ultra-frail adults with multiple myeloma or plasma cell leukemia to help them stay on treatment and feel better.

  Recruiting Phase 2 University of Utah · Chicago, Illinois and 1 other locations · NCT06517017

• Combining venetoclax with isatuximab and dexamethasone for treating relapsed/refractory multiple myeloma

  This study is testing a new combination of medications to see if it can help people with relapsed or stubborn multiple myeloma who have a specific genetic marker feel better and respond to treatment.

  Recruiting at 2 sites Phase 2 Oncotherapeutics · West Hollywood, California and 1 other locations · NCT06115135

• Isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone combination for relapsed/refractory multiple myeloma

  This trial tries the combination of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone to see if it can reduce multiple myeloma in adults whose disease has returned or stopped responding to prior treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT05922501

• Combining Isatuximab and Lenalidomide for High-Risk Multiple Myeloma Patients After Transplant

  This study is testing if combining isatuximab with lenalidomide can help high-risk multiple myeloma patients stay healthy longer after a stem cell transplant.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05776979

• New treatment approach for newly diagnosed multiple myeloma patients

  This study is testing a new combination of treatments for people who have just been diagnosed with multiple myeloma to see if it can help them do better and feel less sick during their care.

  Recruiting at 5 sites Phase 2/3 University Hopsital Schleswig Holstein Campus Lübeck · Berlin and 5 other locations · NCT05665140

• Extended VRD plus vs Isa-VRD vs Isa-V-Iberdomide as part of ASCT in newly diagnosed multiple myeloma

  This trial tests three treatment approaches added to autologous stem cell transplant to see which best clears disease in newly diagnosed myeloma.

  Recruiting at 65 sites Phase 3 PETHEMA Foundation · Alcalá de Henares, Madrid and 67 other locations · NCT05558319

• Maintenance treatment for multiple myeloma after stem cell transplant

  This study is testing if a combination of isatuximab and lenalidomide can help people with multiple myeloma who still have traces of cancer after a stem cell transplant.

  Recruiting at 2 sites Phase 2 University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT05344833

• Combination treatment for transplant ineligible patients with Multiple Myeloma

  This study is testing a new combination treatment for people with newly diagnosed multiple myeloma who can't have a transplant, to see if it helps them feel better and improve their health.

  Recruiting at 7 sites Phase 2 Canadian Myeloma Research Group · Edmonton, Alberta and 6 other locations · NCT05272826

• Using lower doses of isatuximab, lenalidomide, and dexamethasone for older patients with newly diagnosed multiple myeloma

  This study is testing if using lower doses of isatuximab, lenalidomide, and dexamethasone can safely help older patients with newly diagnosed multiple myeloma feel better while reducing side effects.

  Recruiting at 5 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina and 4 other locations · NCT05145400

• Evaluating patient experiences with isatuximab for multiple myeloma

  This study is trying to learn about the experiences of adults with relapsed or refractory multiple myeloma who are receiving isatuximab, by using digital health tools to see how the treatment affects their daily lives over three months.

  Recruiting Pack Health · Houston, Texas and 1 other locations · NCT05053607

• Combining Isatuximab with New Treatments for Refractory Plasma Cell Myeloma

  This study is testing a new combination of isatuximab with other treatments to see if it helps people with tough-to-treat plasma cell myeloma feel better.

  Recruiting at 24 sites Phase 1/2 Sanofi · Atlanta, Georgia and 24 other locations · NCT04643002

• Using NK cells and Isatuximab for treating multiple myeloma after stem cell transplant

  This study is testing whether using natural killer cells alone or with Isatuximab can help people with newly diagnosed multiple myeloma feel better after a stem cell transplant.

  Recruiting Phase 2 Karolinska Institutet · Stockholm · NCT04558931

• Combination treatment for multiple myeloma patients with kidney issues

  This study is testing a new combination treatment for people with multiple myeloma and kidney problems to see if it helps them respond better to therapy before a stem cell transplant.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04240054

Quick answers

How many clinical trials of Isatuximab are recruiting right now?

23, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in United States (12 trials), China (4 trials), Germany (3 trials), Italy (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 15, Phase 1/2: 2, Phase 3: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →